Homology Medicines, Inc. (FIXX)
| Market Cap | 347.10M |
| Revenue (ttm) | 33.04M |
| Net Income (ttm) | -89.60M |
| Shares Out | 56.50M |
| EPS (ttm) | -1.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,636 |
| Open | 6.10 |
| Previous Close | 6.08 |
| Day's Range | 5.99 - 6.16 |
| 52-Week Range | 5.94 - 15.24 |
| Beta | -0.45 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+278.3%) |
| Est. Earnings Date | Nov 8, 2021 |
About FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the live...
Financial Performance
In 2020, FIXX's revenue was $2.70 million, an increase of 62.18% compared to the previous year's $1.67 million. Losses were -$128.69 million, 23.8% more than in 2019.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for FIXX stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is an increase of 278.29% from the latest price.
News
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinic...
- Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of juMPStart and pheEDIT Trials -
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults...
- juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome -
Homology Medicines Announces World's First Gene Editing Clinical Trial for PKU
- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach -
Implied Volatility Surging for Homology Medicines (FIXX) Stock Options
Investors need to pay close attention to Homology Medicines (FIXX) stock based on the movements in the options market lately.
Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of 6.90% and 249.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Homology Medicines (FIXX) Reports Q1 Loss, Tops Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of 96.92% and 3681.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End -
Will Homology Medicines (FIXX) Report Negative Q1 Earnings? What You Should Know
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
- Data From Company's PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations -
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership -
Why Homology Medicines Stock Is Sinking Today
Dilution is on the way thanks to the company's latest stock offering.
Homology Medicines Announces Pricing of Public Offering of Common Stock
BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for...
Homology Medicines Announces Proposed Public Offering of Common Stock
BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subjec...
Homology Medicines (FIXX) Surges 5.9%: Is This an Indication of Further Gains?
Homology Medicines (FIXX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...
Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End -
Earnings Preview: Homology Medicines (FIXX) Q4 Earnings Expected to Decline
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Homology Medicines Regains Global Rights To Novartis Ophthalmology Program
Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing...
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing ...
- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication -
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for H...
- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease -
Homology Medicines: $60 Million Pfizer Equity-Investment, 4 Encouraging Candidates, And Competent Management
Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102...
Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase -
Homology Medicines News: 9 Things for FIXX Stock Investors to Know About the Pfizer Deal
Homology Medicines (FIXX) is making news on Monday after announcing a massive $60 million investment deal with Pfizer (PFE) The post Homology Medicines News: 9 Things for FIXX Stock Investors to Know Ab...